 |
市场调查报告书
商品编码
1629602
血铁沉着症症市场按类型、诊断方法（血液检测、影像技术）、治疗类型、年龄层、最终用户和地区划分Hemochromatosis Market, By Type, By Diagnosis Method (Blood Tests, Imaging Techniques, By Treatment Type, By Age Group, By End User, By Geography |
||||||
2024 年全球血铁沉着症市场规模估计为 16 亿美元，预计 2031 年将达到 24.1 亿美元，2024 年至 2031 年的复合年增长率为 6%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2023 | 2024 年的市场规模 | 16亿美元 |
| 效能资料 | 2019 年至 2023 年 | 预测期 | 2024 年至 2031 年 |
| 预测期间 2024 年至 2031 年复合年增长率： | 6.00％ | 2031 年价值预测 | 24.1亿美元 |
有几个因素推动了对血铁沉着症治疗和管理的需求，包括遗传性血铁沉着症盛行率的增加和对铁超载的认识的提高。
市场动态：
全球血铁沉着症市场的成长主要受到全球遗传性血铁沉着症盛行率上升的推动。 Medscape 估计，到 2023 年 6 月，大约有 100 万美国人将患有遗传性血铁沉着症并且未被诊断。提高对铁过载早期诊断和治疗的认识将对市场成长产生积极影响。此外，越来越多地采用筛检计划来早期发现血铁沉着症，进一步推动了市场的成长。然而，进行基因测试和肝臟切片检查的高成本可能会在一定程度上阻碍市场的成长。然而，对先进诊断方法的开发和基因检测的采用的持续研究预计将在预测期内为市场参与者创造有利可图的机会。
本研究的主要特点
本报告对全球血铁沉着症市场进行了详细分析，并提供了预测期（2024-2031 年）的市场规模（十亿美元）和年复合成长率（CAGR%），假设基准年为 2023 年。
它还强调了各个领域的潜在商机并说明了该市场的有吸引力的投资提案矩阵。
它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球血铁沉着症市场的主要企业。
本研究涉及的主要企业包括诺华公司、赛诺菲公司、安进公司、武田製药有限公司、辉瑞公司、Ironwood Pharmaceuticals, Inc.、Celgene Corporation、基因泰克公司、第一三共株式会社、Teva Pharmaceutical Industries Ltd.、HemoShear Therapeutics, LLC、Erytech Pharmar、Allam
本报告的见解将使负责人和企业经营团队能够就未来产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
相关人员可以透过全球血铁沉着症市场分析中使用的各种策略矩阵来促进他们的决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要进展
- 监管情景
- 产品发布/核准
- PEST分析
- PORTER 分析
- 併购情景
- 产业趋势
4. 2019 年至 2031 年全球血铁沉着症市场（按类型）
- 原发性血铁沉着症（遗传性）
- 次发性血铁沉着症症（后天）
5. 全球血铁沉着症市场，依诊断方法，2019 年至 2031 年
- 血液检查
- 血清铁蛋白
- 转铁蛋白饱和度
- 成像技术
- 磁振造影（MRI）
- 电脑断层扫描 (CT)
- 切片检查
- 基因检测
6. 2019 年至 2031 年全球血铁沉着症市场（依治疗类型）
- 放血
- 螯合疗法
- 饮食管理
- 其他的
7. 2019 年至 2031 年按年龄组别分類的全球血铁沉着症市场
- 孩子们
- 成人
- 老年人
8. 全球血铁沉着症市场，依最终用户划分，2019 年至 2031 年
- 医院
- 诊断实验室
- 手术中心
- 家庭护理设置
9. 2019 年至 2031 年全球血铁沉着症市场（按地区划分）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第十章 竞争格局
- Novartis AG
- Sanofi SA
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma SA
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
第 11 章 分析师建议
- 命运之轮
- 分析师观点
- 一致的机会图
第 12 章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
The global hemochromatosis market is estimated to be valued at USD 1.60 Bn in 2024 and is expected to reach USD 2.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 1.60 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.00% | 2031 Value Projection: | US$ 2.41 Bn |
Several factors such as increasing prevalence of hereditary hemochromatosis and rising awareness regarding iron overload disorders are driving the demand for hemochromatosis treatment and management.
Market Dynamics:
The global hemochromatosis market growth is primarily driven by the rising prevalence of hereditary hemochromatosis across the globe. As per estimates from Medscape, in June 2023, around 1 million Americans suffer from hereditary hemochromatosis which remains undiagnosed. Increasing awareness about the early diagnosis and treatment of iron overload disorders is positively impacting the market growth. Moreover, increasing adoption of screening programs for the early detection of hemochromatosis is further fueling the market growth. However, high costs associated with genetic testing and liver biopsy procedures may hinder the market growth to some extent. Nevertheless, ongoing research for the development of advanced diagnostics and introduction of genetic testing are expected to create lucrative opportunities for market players over the forecast period.
Key Features of the Study:
This report provides in-depth analysis of the global hemochromatosis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemochromatosis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study Novartis AG, Sanofi S.A., Amgen Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Ironwood Pharmaceuticals, Inc., Celgene Corporation, Genentech, Inc., Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., HemoShear Therapeutics, LLC, Erytech Pharma S.A., Alnylam Pharmaceuticals, Inc., HemaCare Corporation, and Invitae Corp.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global hemochromatosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemochromatosis market.
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2031)
- Primary Hemochromatosis (Hereditary)
- Secondary Hemochromatosis (Acquired)
- By Diagnosis Method Insights (Revenue, USD Bn, 2019 - 2031)
- Blood Tests
- Serum Ferritin
- Transferrin Saturation
- Imaging Techniques
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) scans
- Liver Biopsy
- Genetic Testing
- By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Phlebotomy
- Chelation Therapy
- Dietary Management
- Others
- By Age Group Insights (Revenue, USD Bn, 2019 - 2031)
- Pediatric
- Adult
- Geriatric
- By End User Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Diagnostic Laboratories
- Surgical Centers
- Home Care Settings
- Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Sanofi S.A.
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma S.A.
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Hemochromatosis Market, By Type
- Global Hemochromatosis Market, By Diagnosis Method
- Global Hemochromatosis Market, By Treatment Type
- Global Hemochromatosis Market, By Age Group
- Global Hemochromatosis Market, By End User
- Global Hemochromatosis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Hemochromatosis Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Primary Hemochromatosis (Hereditary)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Secondary Hemochromatosis (Acquired)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Hemochromatosis Market, By Diagnosis Method, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Blood Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Serum Ferritin
- Transferrin Saturation
- Imaging Techniques
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) scans
- Liver Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Hemochromatosis Market, By Treatment Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Phlebotomy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Chelation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Dietary Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Hemochromatosis Market, By Age Group, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Global Hemochromatosis Market, By End User, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
9. Global Hemochromatosis Market, By Region, 2019 - 2031, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Diagnosis Method, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Ironwood Pharmaceuticals, Inc.
- Celgene Corporation
- Genentech, Inc.
- Daiichi Sankyo Company, Limited
- Teva Pharmaceutical Industries Ltd.
- HemoShear Therapeutics, LLC
- Erytech Pharma S.A.
- Alnylam Pharmaceuticals, Inc.
- HemaCare Corporation
- Invitae Corp.
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
